Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The scariest part of the Talon story is its balance sheet. Talon's fully diluted share count is not the 21 million listed on Yahoo Finance. In reality, the company has 140 million shares outstanding when all convertible preferred shares owned by Warburg Pincus and Deerfield Capital are factored in, says Talon CFO Craig Carlson. So, at a share price of $1.10, Talon's true market cap is $154 million, not the $23 million listed in Yahoo Finance.
Talon is not a cheap stock. And the share count is headed higher because Talon needs to raise a lot more cash to market Marqibo and pay for the confirmatory phase III study mandated by FDA. That trial is going to cost $42 million, says Deitcher.
In our conversation, Deitcher mentioned plans to seek an ex-U.S. partner for Marqibo that could help the company raise additional non-dilutive cash. He also hinted that large pharmaceutical companies might want to acquire Talon outright. Talon as takeover bait? Really? Marqibo is nothing more than a reformulation of vincristine, an old chemotherapy drug -- hard to see it as a highly sought-after product but heck, stranger things have happened.
From the Street.com
vidpok45, negative. From the horse's mouth..240 mg..
Yep, now at 240 mg.
To me, one of the best atributes of Harvey is that he delivers. Over the last two years, every item he said Ariad would do, they did.. Certainly is a different Harvey from the days of the BOD scandal and the patent issue disaster..
vidpok45, I'm impressed.. You just created the first Ariad Do Loop!
Harvey on FOX tonight... Ariad Pharmaceuticals Working on Cancer ‘Miracle Pill’
Hear him say, "Pona approval late this year or early next year". Sigh, he was not with Liz... We rock on Monday..
http://video.foxbusiness.com/v/1769395067001/ariad-pharmaceuticals-working-on-cancer-miracle-pill
The issue is she has had a neutral from $5 to $19.72. Her analysis is fine, in fact, her model values '113 higher ($6) than anyone on the street. A neutral in some camps is considered a closet sell, by the way..
Rachel McMinn should cover just big pharma as she doesn't understand the leverage that a small biotech can deliver to it's shareholders. If Merrill was smart, they would have only cover PFE, MRK, NVS, etc., as that is her mindset Still neutral. Pathetic.
OK contrarian investors, trading in Ariad options today showed a 2.49 put/call ratio. Let's show the shorts what's wrong in their thinking..
http://www.avafin.com/articles/1016409.html
Which we could have had the 4 upgrades in the $25-$27 share price range AFTER earnings..
Cash and cash equivalants to fund operations TO Q4 2013.
All but certain that we will have a secondary after approval of Pona in Q1 2013, but that will be perfect timing..
$162 million consumed in 2012
gpo3.44,- 2. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2011.
This was with most of the filings with the Form 4 filed tonight. Some were direct and not option related. Small sums. Please read the filings before posting..
They are leaning hard..................
Ariad Pharm (NASDAQ:ARIA): Rodman & Renshaw reiterated its rating of Mkt Outperform for this company and changed its price target from $22 to $26.
I think that makes four upgrades to the $25-$27 range.
Ariad Pharm (NASDAQ:ARIA): Rodman & Renshaw reiterated its rating of Mkt Outperform for this company and changed its price target from $22 to $26.
I think that makes four in the $25-$27 range.
Can anyone post the Rodman & Renshaw report? They are usually quite informative..
Dew, your math with PFE needs a little work as you compare your "annualized" emerging market to the 2Q12 sales results of PFE.
You said, "The base is not small. In 2Q12, PFE had $10.5B of annualized sales in emerging markets".
I didn't dig back to where you got that data. Let's convert that back to $2.6B per quarter. What were the actual China sales, by the way?
So from below the US sales $5.7B, + Int'l $9.3B, yields $15B total for Q2. Emerging markets is then $2.6B /$15B = 17% of total sales. As I said, it is a start, and represents the fastest growth area.
NEW YORK, N.Y., Tuesday, July 31, 2012 – Pfizer Inc. (NYSE: PFE) today reported financial
results for second-quarter 2012. Second-quarter 2012 revenues were $15.1 billion, a decrease of
9% compared with $16.5 billion in the year-ago quarter, which reflects an operational decline of
$977 million, or 6%, and the unfavorable impact of foreign exchange of $451 million, or 3%.
For second-quarter 2012, U.S. revenues were $5.7 billion, a decrease of 15% compared with the
year-ago quarter. This decrease was primarily the result of the U.S. loss of exclusivity of Lipitor
on November 30, 2011. International revenues were $9.3 billion, a decrease of 5% compared
PFE sales were down 15% in the US, and down 5% Internationally. The BRIC sales must be in the noise..
NEW YORK, N.Y., Tuesday, July 31, 2012 – Pfizer Inc. (NYSE: PFE) today reported financial
results for second-quarter 2012. Second-quarter 2012 revenues were $15.1 billion, a decrease of
9% compared with $16.5 billion in the year-ago quarter, which reflects an operational decline of
$977 million, or 6%, and the unfavorable impact of foreign exchange of $451 million, or 3%.
For second-quarter 2012, U.S. revenues were $5.7 billion, a decrease of 15% compared with the
year-ago quarter. This decrease was primarily the result of the U.S. loss of exclusivity of Lipitor
on November 30, 2011. International revenues were $9.3 billion, a decrease of 5% compared
This is almost surreal.........
Dewdiligence, you may want to re-read the Ariad PR:
"The company said it will submit additional data on matters including the manufacturing and chemistry of ponatinib during the third quarter. Ariad also plans to file for marketing approval in Europe during the current quarter."
I see nothing "sleazy" about the PR.
These guys are a marketing machine!! Perfect timing on the NDA!!
Good point!
Upgrade to $27, and another start at $25 today, can Merrill's McMinn be that far from moving off her FOREVER hold on Ariad? LOL..
FWIW- News for 'ARIA' - (*DJ Ariad Pharmaceuticals Started At Outperform By William Blair >ARIA)
(END) Dow Jones Newswires
July 30, 2012 06:47 ET (10:47 GMT)
An interesting thought from Peter over at BV on Pona:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=77927824
Yes, the up to 176 sites is good news, but it will cost them a small fortune.. That has me thinking.....
Ariad has really ran their PR machine very well over the last 18 months, so it wouldn't surprise me if they do announce the NDA filing on the earnings call. Seems though to me that it would be a lttle early as I was expecting mid September..
MERCK- Marty is a double agent from Merck dedicated to winning Ariad for Merck. lol.. Seriously, Marty is a really valuable catch for Ariad.. Read all about him at Ariad.com
Give Ariad a little slack. AP26113 and LDK378 are early stage compounds, with LDK378 just six or so months ahead of AP26113. They are in Phase I trials, soon to enter phase II! It's early partner!
mejs, that is the best W.A.S. I've seen in a long, long time..
Rodman ups Ariad share price to $22
Ariad Pharmaceuticals Inc. (NASDAQ:ARIA): According to Rodman & Renshaw, the upward trend for Novartis’ chronic myelogenous leukemia drugs creates a positive read-through for the second-line CML treatment ponatinib from ARIAD (NASDAQ:ARIA). Rodman increased ARIAD’s price target to $22 but keeps its Market Outperform rating on the stock.
Where I disagree, is that I consider Ariad's Ponatinib as a third line CML drug..
Not much.
Don, could they stop at 120 mg for ALK+, and continue on increasing the dose for EGFR, and then have two phase II trials, one for ALK+ and the other for EGFR?
Elton John's "Rocket Man" was playing just as we marked a new 52 week high... Imagine that!
It was huge.